Fig. 3: PRMT9 inhibits innate antiviral response in vivo.
From: The protein arginine methyltransferase PRMT9 attenuates MAVS activation through arginine methylation
a–d Eight-week male Prmt9CKO and Prmt9WT mice were infected by tail vein injection with VSV (1.8 × 107 PFU per mouse) for 24 h (n = 6 mice per group). a qRT-PCR analysis of Ifnb1 mRNA in the lung (left, ***p = 0.0009), liver (middle, **p = 0.0059), and spleen (middle, *p = 0.0119). b ELISA analysis of IFN-β protein in serum, ***p = 0.0002. Plaque assay of VSV titers (c) and qRT-PCR analysis of VSV mRNA (d) in lung (left, ***p = 0.0001), liver (middle, ***p  = 0.0005) and spleen (right, ***p = 0.0028). e, f Survival of Prmt9CKO and Prmt9WT mice (n = 12 mice per group, 6–8 weeks old) after tail vein injection with VSV (1 × 108 PFU per mouse) or HSV-1 (1.5 × 108 PFU per mouse). e: *p = 0.0133, f: ns = 0.7923. g Hematoxylin-eosin staining of lung sections were presented, treated as in a (n = 6 mice per group). Scale bar, 50 μm. Inflammation scores of lung tissue sections described in g (*p = 0.0106). The qRT-PCR and ELISA results are presented relative to those of untreated wild-type tissue cells (a, b and d). Data are shown as mean ± SD (a–g) and are representative of three independent experiments with similar results. *P < 0.05; **P < 0.01; ***P < 0.001 (two-tailed student’s t-test in a–d, g or the log-rank Mantel-Cox test in e, f).
